RBC Capital downgraded Axonics (AXNX) to Sector Perform from Outperform with a price target of $71, up from $69, after the company entered into a definitive agreement to be acquired by Boston Scientific (BSX) for $71 in cash per share, representing an equity value of approximately $3.7B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXNX:
- M & A News: Boston Scientific (NYSE:BSX) to Acquire Axonics in $3.7B Deal
- Boston Scientific Announces Agreement to Acquire Axonics, Inc.
- 5 Top MedTech Stocks for 2024, According to Analysts from Baird
- Axonics price target raised to $73 from $65 at Truist
- NeuroPace price target raised to $8 from $6 at Morgan Stanley
